NYSE:GRDN Guardian Pharmacy Services (GRDN) Stock Price, News & Analysis $41.27 -0.60 (-1.43%) As of 10:40 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Guardian Pharmacy Services Stock (NYSE:GRDN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GRDN alerts:Sign Up Key Stats Today's Range$40.54▼$41.6850-Day Range$34.99▼$43.4352-Week Range$19.30▼$44.00Volume40,995 shsAverage Volume396,317 shsMarket Capitalization$2.05 billionP/E Ratio49.38Dividend YieldN/APrice Target$42.83Consensus RatingModerate Buy Company Overview Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia. Read More Guardian Pharmacy Services Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreGRDN MarketRank™: Guardian Pharmacy Services scored higher than 30% of companies evaluated by MarketBeat, and ranked 703rd out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingModerate Buy Consensus RatingGuardian Pharmacy Services has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Guardian Pharmacy Services is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageGuardian Pharmacy Services has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Guardian Pharmacy Services' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth11.02% Earnings GrowthEarnings for Guardian Pharmacy Services are expected to grow by 11.02% in the coming year, from $1.18 to $1.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Guardian Pharmacy Services is 50.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.69.Price to Earnings Ratio vs. SectorThe P/E ratio of Guardian Pharmacy Services is 50.50, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.24.Price to Earnings Growth RatioGuardian Pharmacy Services has a PEG Ratio of 2.65. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGuardian Pharmacy Services has a P/B Ratio of 12.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Guardian Pharmacy Services' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.72% of the float of Guardian Pharmacy Services has been sold short.Short Interest Ratio / Days to CoverGuardian Pharmacy Services has a short interest ratio ("days to cover") of 8.67.Change versus previous monthShort interest in Guardian Pharmacy Services has recently increased by 11.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGuardian Pharmacy Services does not currently pay a dividend.Dividend GrowthGuardian Pharmacy Services does not have a long track record of dividend growth. News and Social Media1.6 / 5News SentimentN/A News SentimentGuardian Pharmacy Services has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Guardian Pharmacy Services this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for GRDN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Guardian Pharmacy Services to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Guardian Pharmacy Services insiders have not sold or bought any company stock.Percentage Held by Insiders32.96% of the stock of Guardian Pharmacy Services is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsGuardian Pharmacy Services has minimal institutional ownership at this time.Read more about Guardian Pharmacy Services' insider trading history. Receive GRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardian Pharmacy Services and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRDN Stock News HeadlinesGuardian Pharmacy Services (NYSE:GRDN) & SCYNEXIS (NASDAQ:SCYX) Head to Head ContrastJune 30 at 3:52 AM | americanbankingnews.comGuardian Pharmacy Announces Leadership Transition and PromotionsJune 22, 2026 | tipranks.comPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.July 1 at 1:00 AM | Weiss Ratings (Ad)Guardian Pharmacy Services, Inc. Announces Leadership TransitionsJune 22, 2026 | businesswire.comGuardian Pharmacy Extends Revolving Credit Facility and FlexibilityMay 28, 2026 | tipranks.comStatutory Profit Doesn't Reflect How Good Guardian Pharmacy Services' (NYSE:GRDN) Earnings AreMay 14, 2026 | finance.yahoo.comGuardian Pharmacy Services, Inc. (GRDN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comGuardian Pharmacy Services Signals Strength Amid IRA ShockMay 10, 2026 | tipranks.comSee More Headlines GRDN Stock Analysis - Frequently Asked Questions How have GRDN shares performed this year? Guardian Pharmacy Services' stock was trading at $30.01 at the start of the year. Since then, GRDN stock has increased by 39.7% and is now trading at $41.9170. How were Guardian Pharmacy Services' earnings last quarter? Guardian Pharmacy Services, Inc. (NYSE:GRDN) released its earnings results on Wednesday, May, 6th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.05. The company's revenue for the quarter was up 2.2% on a year-over-year basis. Read the conference call transcript. When did Guardian Pharmacy Services IPO? Guardian Pharmacy Services (GRDN) raised $102 million in an initial public offering on Thursday, September 26th 2024. The company issued 6,800,000 shares at $14.00-$16.00 per share. Raymond James, Stifel and Truist Securities served as the underwriters for the IPO. How do I buy shares of Guardian Pharmacy Services? Shares of GRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Guardian Pharmacy Services own? Based on aggregate information from My MarketBeat watchlists, some other companies that Guardian Pharmacy Services investors own include UnitedHealth Group (UNH) and Meta Platforms (META). Company Calendar Last Earnings5/06/2026Today7/01/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 GRDN's financial health is in the Green zone, according to TradeSmith. GRDN has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - DRUGS Sub-IndustryRetail Current SymbolNYSE:GRDN Previous SymbolNYSE:GRDN CIK1802255 Webguardianpharmacy.com Phone(404) 810-0089FaxN/AEmployees3,600Year Founded2004Price Target and Rating Average Price Target for Guardian Pharmacy Services$42.83 High Price Target$47.00 Low Price Target$36.00 Potential Upside/Downside+4.5%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$0.83 Trailing P/E Ratio49.40 Forward P/E Ratio34.75 P/E Growth2.65Net Income$49.22 million Net Margins3.64% Pretax Margin5.40% Return on Equity30.72% Return on Assets15.99% Debt Debt-to-Equity RatioN/A Current Ratio1.46 Quick Ratio1.17 Sales & Book Value Annual Sales$1.45 billion Price / Sales1.41 Cash Flow$1.28 per share Price / Cash Flow32.11 Book Value$3.44 per share Price / Book11.92Miscellaneous Outstanding Shares49,780,000Free Float33,373,000Market Cap$2.04 billion OptionableN/A Beta0.08 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NYSE:GRDN) was last updated on 7/1/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guardian Pharmacy Services, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Guardian Pharmacy Services With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRDN Stock Alerts